Cancer Immunotherapy Clinic

Study of bb21217 in Multiple Myeloma

Incidence of adverse events (AEs) and abnormal laboratory test results, including dose limiting toxicities (DLTs)

Recruiting

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Adv...

Recruiting

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in ...

Dose limiting toxicity (DLT) is defined as protocol-defined adverse events that occur within 28 days following infusion of Neo-TCR-P1 administered as a single agent or in combination with nivolumab.

Recruiting

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malig...

Incidence of adverse events (AEs) observed across STRO-001 dose levels

Recruiting

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Only patients in cohort 2, who achieve testosterone recovery to non-castrate levels (>150 ng/dL) at 15 months, will be analyzed for the primary endpoint. The rate of PSA < nadir + 2 ng/mL at 15 months from the start of radiotherap...

Recruiting

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Infor...

Recruiting

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Da...

Radiographic progression free survival (rPFS) is defined as the time from the first day of study treatment with pembrolizumab to the date of documented radiographic tumor progression or death due to any cause, whichever occurs fir...

Recruiting

Study of MK-1454 Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Adva...

DLTs will be assessed during the first cycle (21 days) & are defined as: Grade (Gr) 4 nonhematologic toxicity; Gr 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia, Gr 4 thrombocytopenia, Gr 3 thrombocytopenia (if as...

Recruiting

Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumor...

The proportion of participants who show clinical benefit, defined as complete response (CR), partial response (PR), or stable disease (SD) for ≥ 6 months as best response by RECIST v1.1

Recruiting

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Incidence and severity of treatment-emergent adverse events

Recruiting